Transmission of RV5 Strain Occurs Infrequently in Neonatal ICU
THURSDAY, Dec. 12, 2024 -- Transmission of the pentavalent rotavirus vaccine (RV5) strain is infrequent in the neonatal intensive care unit (NICU) and does not have clinical consequences, according to a study published online Dec. 9 in Pediatrics.
Morgan A. Zalot, M.P.H., from the Children's Hospital of Philadelphia, and colleagues conducted a prospective cohort study involving all patients admitted to a 100-bed NICU for one year. Stool samples were collected weekly, and any RV5 strain was detected using real-time quantitative reverse-transcription polymerase chain reaction. The incidence of transmission to unvaccinated infants was calculated.
Overall, 1,238 infants were admitted; 45 percent were premature and 26 percent had gastrointestinal pathology. A total of 226 RV5 doses were administered during observation. The researchers tested 3,448 stool samples, including 2,252 from 686 unvaccinated patients. The majority (99.3 percent) of unvaccinated patients never tested positive for RV5; five (<1 percent) tested positive. The estimated transmission rate was 5/2,252 stools per unvaccinated infants or 2.2 per 1,000 patient-days at risk. In transmission cases, there were no gastroenteritis symptoms identified within seven days of collection of an RV5-positive stool. Fifty-five percent of the 126 patients for whom the RV5 series was initiated before the discharge date would have become age-ineligible to start the series if vaccination was allowed only at discharge.
"These findings add to the existing safety data and suggest that the known benefits of NICU administration of RV5 outweigh the low risks of vaccine-strain transmission," the authors write.
One author disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Higher Tattoo Exposure Linked to Reduced Melanoma Risk
MONDAY, Sept. 29, 2025 -- Higher tattoo exposure may be associated with reduced melanoma risk, according to a study published online Aug. 21 in the Journal of the National Cancer...
Antithymocyte Globulin Cuts Loss of β-Cell Function in Type 1 Diabetes
MONDAY, Sept. 29, 2025 -- Antithymocyte globulin (ATG) 2.5 and 0.5 mg/kg reduces loss of β-cell function in young people with recent-onset type 1 diabetes, according to a...
Loss of Therapeutic Benefit Seen After Stopping Baricitinib in Type 1 Diabetes
MONDAY, Sept. 29, 2025 -- Two-year follow-up shows a loss of therapeutic benefit when baricitinib treatment is stopped in type 1 diabetes (T1D), according to a study presented at...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.